A new trading day began on Monday, with Mineralys Therapeutics Inc (NASDAQ: MLYS) stock price up 3.88% from the previous day of trading, before settling in for the closing price of $13.40. MLYS’s price has ranged from $8.24 to $18.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -2.23%. With a float of $38.25 million, this company’s outstanding shares have now reached $49.82 million.
The firm has a total of 51 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 41.04%, while institutional ownership is 44.70%. The most recent insider transaction that took place on Apr 14 ’25, was worth 165,185. Before that another transaction happened on Apr 11 ’25, when Company’s Officer proposed sale 10,757 for $12.06, making the entire transaction worth $129,684.
Mineralys Therapeutics Inc (MLYS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -2.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.77% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Here are Mineralys Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.64, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -3.82 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Analysing the last 5-days average volume posted by the [Mineralys Therapeutics Inc, MLYS], we can find that recorded value of 1.34 million was better than the volume posted last year of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 49.75%. Additionally, its Average True Range was 1.51.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 56.01%, which indicates a significant increase from 51.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.43% in the past 14 days, which was higher than the 98.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.20, while its 200-day Moving Average is $12.27. Now, the first resistance to watch is $14.68. This is followed by the second major resistance level at $15.43. The third major resistance level sits at $16.04. If the price goes on to break the first support level at $13.32, it is likely to go to the next support level at $12.71. Now, if the price goes above the second support level, the third support stands at $11.95.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
With a market capitalization of 873.90 million, the company has a total of 62,785K Shares Outstanding. Currently, annual sales are 0 K while annual income is -177,810 K. The company’s previous quarter sales were 0 K while its latest quarter income was -48,950 K.
